Market Trends of Coronary Artery Disease Therapeutics Industry
This section covers the major market trends shaping the Coronary Artery Disease Therapeutics Market according to our research experts:
Statins Segment is Expected to Hold a Significant Market Share in the Coronary Artery Disease Therapeutics Market Over the Forecast Period.
Statin medications are drugs that help to lower cholesterol levels in the blood and prevent coronary heart disease. Statins are the first-line treatment of choice for patients with coronary heart disease and high cholesterol levels. These drugs have additional benefits such as improvements in endothelial function, reduction in the amount of inflammation and damage done to cells through oxidation stress, and prevention of platelet aggregation, thereby reducing the risk of a blood clot (thrombus).
The statins segment holds a significant market share in the coronary artery disease therapeutics market. It is anticipated to show a similar trend over the forecast period due to its ability to reduce mortality and cardiovascular events in patients with coronary artery disease or at high risk of cardiovascular disease. According to the study published in the Journal of Cardiothoracic Imaging in April 2022, baseline statin medication was related to a reduction in major cardiovascular events in people with non-obstructive coronary artery disease (CAD). Statins act by lowering levels of low-density lipoprotein cholesterol, reducing the substrate for plaque formation, and can also stabilize plaques by favorably changing the plaque pathophysiology. Thus, the above benefits of statin therapy in the CAD are expected to increase demand for statins, thereby boosting segment growth.
Moreover, rising approvals of the statins are further expected to boost the market growth. For instance, in March 2021, the FDA approved Althera Pharmaceutical's Roszet (rosuvastatin/ezetimibe) in patients with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C). Such approvals are anticipated to drive segment growth due to the rise in the adoption of statins.
Therefore, the rising approvals of statins and the importance of statins as a first-line treatment in the management of CAD are the factors expected to drive segment growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global coronary artery disease therapeutics market due to the growing geriatric population, strong foothold of major market players, and increasing incidences of coronary artery disease.
The rising prevalence of coronary artery disease in the United States is expected to drive the growth of the market studied in the region. For instance, according to CDC, in 2022, the percentage of coronary heart disease for adults aged 18 and over in the United States 2021 is 4.9%. Such a huge prevalence is anticipated to drive market growth due to the rising adoption of therapies in these patients.
Moreover, continuous product approval in the segment is expected to drive segment growth. For instance, in August 2021, Health Canada approved MYINFLA 0.5 mg for the reduction of cardiovascular risk in patients with coronary disease. In addition, in February 2022, FDA approved Norliqva (amlodipine) oral solution for the treatment of hypertension in adults and children 6 years and older and coronary artery disease. Thus, such advances in the region are anticipated to drive market growth over the forecast period.
Thus, the market is expected to witness a high growth rate over the forecast period due to the factors mentioned above in the North American region. Furthermore, high healthcare spending and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.
